311C90: patient profiles and typical case histories of migraine management.
The 311C90 (Zomig; zolmitriptan) long-term safety and efficacy study includes data from > 30,000 treated migraine attacks across > 2,000 patients. A review of the database identified individuals who were representative of the population studied within this trial to illustrate the findings from a patient perspective. Five case histories are described here. These patients were identified on the basis of lying at the midpoint of the trial population sample with reference to certain baseline characteristics, and therefore representing a "typical" patient. The case histories represent a "typical" man and woman patient, a patient who has migraine with aura, a patient with frequent migraine accompanied by a high frequency of adverse events, and a patient with frequent migraine attacks, some of which were related to menses. The results show that 311C90 was consistently effective for these individual patients across a number of treated attacks in the acute treatment of migraine. It is concluded that consideration of data at the individual patient level allows appreciation of clinical benefit from a different but valuable perspective.
Dowson
A J
AJ
Kings Headache Service, Kings College Hospital, London, UK.
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008598:Menstruation; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D013997:Time Factors; D014363:Tryptamines
D010080:Oxazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan